Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03361436 · ClinicalTrials.gov registry record · Phase 1

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

A Phase 1 study of Malignant Solid Neoplasm and Liposarcoma, sponsored by OHSU Knight Cancer Institute.

Active
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT03361436 is a Phase 1 study of Malignant Solid Neoplasm and Liposarcoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 15 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03361436, a Phase 1 study of Malignant Solid Neoplasm and Liposarcoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This phase Ib trials studies the side effects and best dose of eribulin mesylate when given together with radiation therapy in treating patients with retroperitoneal liposarcoma that can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells.

Conditions Studied

Malignant Solid Neoplasm Liposarcoma Malignant Abdominal Neoplasm Malignant Retroperitoneal Neoplasm Malignant Scrotal Neoplasm Malignant Spermatic Cord Neoplasm

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • OTHER Questionnaire Administration
  • RADIATION Intensity-Modulated Radiation Therapy
  • DRUG Eribulin Mesylate

Study Locations (1)

Oregon

  • OHSU Knight Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2018-03-19
Est. Completion 2033-04-14
Phase Phase 1

Sponsor

OHSU Knight Cancer Institute

211 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03361436

The ClinicalTrials.gov registry entry for NCT03361436 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (99% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03361436 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT03361436 about?

NCT03361436 is a clinical study titled "Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery". This phase Ib trials studies the side effects and best dose of eribulin mesylate when given together with radiation therapy in treating patients with retroperitoneal liposarcoma that can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the ...

What is the current status of trial NCT03361436?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-03-19. Estimated completion is 2033-04-14.

What conditions does trial NCT03361436 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Scrotal Neoplasm.

What interventions are being tested in trial NCT03361436?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Intensity-Modulated Radiation Therapy (RADIATION), Eribulin Mesylate (DRUG).

Who is sponsoring clinical trial NCT03361436?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03361436 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Neoplasm

All registered trials for this condition

Liposarcoma

All registered trials for this condition

Oregon

All trials with a study site in Oregon

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.